Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Yandomized, double-blind, placebo-controlled study

Journal of Clinical Psychopharmacology

Volumn 33, Issue 3, 2013, Pages 336-342

  Rezaei, Farzin ^a   Mohammad Karimi, Maryam ^b   Seddighi, Sahar ^c   Modabbernia, Amirhossein ^b   Ashrafi, Mandana ^b   Salehi, Bahman ^c   Hammidi, Siran ^a   Motasami, Hamid ^a   Hajiaghaee, Reza ^d   Tabrizi, Mina ^e   Akhondzadeh, Shahin ^b  

^a KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d AVICENNA RESEARCH INSTITUTE   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

add on; Memantine; negative symptoms; NMDA receptor antagonist; primary; schizophrenia

Indexed keywords

MEMANTINE; PLACEBO; RISPERIDONE;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; EXTRAPYRAMIDAL SYMPTOM RATING SCALE; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; INCREASED APPETITE; MALE; NAUSEA; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MEMANTINE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84877583223     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31828b50a7     Document Type: Article

References (48)

1. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry. 1991; 48(11): 978-986.
2. Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006; 32(2): 214-219.
3. Murphy BP, Chung YC, Park TW, et al. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res. 2006; 88(1-3): 5-25.
4. Laughren T, Levin R. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr Bull. 2006; 32(2): 220-222.
5. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007; 33(4): 1013-1022.
6. Kucinski AJ, Stachowiak MK, Wersinger SR, et al. Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia. Curr Pharm Biotechnol. 2011; 12(3): 437-448.
7. Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, et al. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(8): 1879-1883.
8. Abbasi SH, Behpournia H, Ghoreshi A, et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res. 2010; 116(2-3): 101-106.
9. Akhondzadeh S, Ghayyoumi R, Rezaei F, et al. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology (Berl). 2011; 213(4): 809-815.
10. Akhondzadeh S, Safarcherati A, Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29(2): 253-259.
11. Ghaleiha A, Noorbala AA, Farnaghi F, et al. A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. J Clin Psychopharmacol. 2010; 30(6): 678-682.
12. Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 2011; 25(10): 859-885.
13. Saunders JA, Gandal MJ, Siegel SJ. NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia. Neurobiol Dis. 2012; 46(1): 93-100.
14. Gilmour G, Dix S, Fellini L, et al. NMDA receptors, cognition and schizophreniaVtesting the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology. 2012; 62(3): 1401-1412.
15. Akhondzadeh S. The glutamate hypothesis of schizophrenia. J Clin Pharm Ther. 1998; 23(4): 243-246.
16. Krivoy A, Weizman A, Laor L, et al. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: a preliminary study. Eur Neuropsychopharmacol. 2008; 18(2): 117-121.
17. de Lucena D, Fernandes BS, Berk M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry. 2009; 70(10): 1416-1423.
18. Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999; 56(1): 21-27.
19. Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, et al. Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J Clin Pharm Ther. 1999; 24(5): 369-374.
20. Gama CS, Antunes P, Moser C, et al. [Memantine as an adjunctive therapy for schizophrenia negative symptoms]. Rev Bras Psiquiatr. 2005; 27(3): 257-258.
21. Thomas C, Carroll BT, Maley RT, et al. Memantine and catatonic schizophrenia. Am J Psychiatry. 2005; 162(3): 626.
22. Carpenter SS, Hatchett AD, Fuller MA. Catatonic schizophrenia and the use of memantine. Ann Pharmacother. 2006; 40(2): 344-346.
23. Carroll BT, Thomas C, Jayanti K. Amantadine and memantine in catatonic schizophrenia. Ann Clin Psychiatry. 2006; 18(2): 133-134.
24. Ponde MP, Novaes CM. Aripiprazole worsening positive symptoms and memantine reducing negative symptoms in a patient with paranoid schizophrenia. Rev Bras Psiquiatr. 2007; 29(1): 92.
25. Lieberman JA, Papadakis K, Csernansky J, et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology. 2009; 34(5): 1322-1329.
26. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261-276.
27. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: 56-62.
28. Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal symptom rating scale. Can J Neurol Sci. 1980; 7(3): 233.
29. Francis PT. Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine. Curr Mol Pharmacol. 2009; 2(1): 77-82.
30. Kavirajan H. Memantine: a comprehensive review of safety and efficacy. Expert Opin Drug Saf. 2009; 8(1): 89-109.
31. Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6): 1362-1374.
32. Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic systemVtoo little activation is bad, too much is even worse. Neuropharmacology. 2007; 53(6): 699-723.
33. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonistVa review of preclinical data. Neuropharmacology. 1999; 38(6): 735-767.
34. Parsons CG, Gruner R, Rozental J, et al. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology. 1993; 32(12): 1337-1350.
35. Black M, Lanthorn T, Small D, et al. Study of potency, kinetics of block and toxicity of NMDA receptor antagonists using fura-2. Eur J Pharmacol. 1996; 317(2-3): 377-381.
36. Parsons CG, Gilling K. Memantine as an example of a fast, voltage-dependent, open channel N-methyl-D-aspartate receptor blocker. Methods Mol Biol. 2007; 403: 15-36.
37. Danysz W, Parsons CG, Mobius HJ, et al. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's diseaseVa unified glutamatergic hypothesis on the mechanism of action. Neurotox Res. 2000; 2(2-3): 85-97.
38. Krystal JH, D'Souza DC, Mathalon D, et al. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl). 2003; 169(3-4): 215-233.
39. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron. 2003; 40(5): 881-884.
40. Paz RD, Tardito S, Atzori M, et al. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol. 2008; 18(11): 773-786.
41. Rammes G, Rupprecht R, Ferrari U, et al. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl- cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett. 2001; 306(1-2): 81-84.
42. Zhang ZJ, Kang WH, Li Q, et al. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr Res. 2006; 88(1-3): 102-110.
43. Akhondzadeh S, Mohammadi N, Noroozian M, et al. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr Res. 2009; 107(2-3): 206-212.
44. Wildeboer KM, Zheng L, Choo KS, et al. Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism. Brain Res. 2009; 1300: 41-50.
45. Bennett AC, Vila TM. The role of ondansetron in the treatment of schizophrenia. Ann Pharmacother. 2010; 44(7-8): 1301-1306.
46. Coan EJ, Collingridge GL. Magnesium ions block an N-methyl-D-aspartate receptor-mediated component of synaptic transmission in rat hippocampus. Neurosci Lett. 1985; 53(1): 21-26.
47. Coan EJ, Collingridge GL. Characterization of an N-methyl-D-aspartate receptor component of synaptic transmission in rat hippocampal slices. Neuroscience. 1987; 22(1): 1-8.
48. Lieberman JA, Perkins DO, Jarskog LF. Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. CNS Spectr. 2007; 12(3 suppl 4): 1-13; quiz 14.